Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06044311 · ClinicalTrials.gov registry record · Phase 2
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
A Phase 2 study of Adenocarcinoma Esophagus and Locally Advanced Adenocarcinoma, sponsored by Sakti Chakrabarti.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06044311 is a Phase 2 study of Adenocarcinoma Esophagus and Locally Advanced Adenocarcinoma that is actively recruiting participants, run by Sakti Chakrabarti. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06044311, a Phase 2 study of Adenocarcinoma Esophagus and Locally Advanced Adenocarcinoma, is actively recruiting participants, sponsored by Sakti Chakrabarti.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This interventional clinical trial aims to find ways of improving treatments for individuals with esophageal cancer. Laboratory-based studies show that using medicines that affect a protein called TGF-beta (TGFβ) can kill esophageal cancer cells in individuals who have localized esophageal adenocarcinoma and are being considered for standard-of-care chemoradiation prior to surgery. Participants of this study will take a pill called vactosertib for two weeks before starting standard of care chemoradiation. At the end of the two weeks of taking vactosertib, participants will have a Positron Emission Tomography Computer Assisted Tomography (PET CT) scan and undergo an endoscopy with a biopsy to determine if the vactosertib is working. After chemoradiation, participants will take vactosertib again for four weeks and then be considered for surgery.
Conditions Studied
Interventions
- DRUG Standard of Care Chemotherapy
- DRUG Vactosertib
- RADIATION Concurrent Radiation
Study Locations (1)
Ohio
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06044311
The ClinicalTrials.gov registry entry for NCT06044311 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sakti Chakrabarti, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Adenocarcinoma Esophagus appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care Chemotherapy is the first listed.
NCT06044311 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06044311 about?
NCT06044311 is a clinical study titled "Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma". This interventional clinical trial aims to find ways of improving treatments for individuals with esophageal cancer. Laboratory-based studies show that using medicines that affect a protein called TGF-beta (TGFβ) can kill esophageal cancer cells in individuals who have localized esophageal adenocarc...
What is the current status of trial NCT06044311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-09-30. Estimated completion is 2027-06-01.
What conditions does trial NCT06044311 study?
This clinical trial studies the following conditions: Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction.
What interventions are being tested in trial NCT06044311?
The interventions under investigation include: Standard of Care Chemotherapy (DRUG), Vactosertib (DRUG), Concurrent Radiation (RADIATION).
Who is sponsoring clinical trial NCT06044311?
This trial is sponsored by Sakti Chakrabarti, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06044311 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.